On September 4, 2019 Adastra Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of proprietary medicines for the treatment of cancer, reported that Scott Megaffin, Chief Executive Officer, will present at the 2019 Janney Healthcare Conference being held September 9-10, 2019, at The Union League Club in New York City (Press release, Adastra Pharmaceuticals, SEP 4, 2019, View Source [SID1234539283]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Megaffin will present Adastra’s corporate growth strategy and clinical plans for its lead candidate, Zotiraciclib, which is designed to treat cancers characterized by Myc overexpression. Adastra is currently evaluating Zotiraciclib in two Phase 1b trials in glioblastoma multiforme (GBM) and a separate Phase 1b study in pediatric diffuse intrinsic pontine glioma (DIPG).

Event:

2019 Janney Healthcare Conference

Date:

Monday, September 9, 2019

Time:

11:50 AM (Eastern Time)

Location:

The Union League Club, New York, NY

Webcast Link:

View Source;eom

The presentation’s audio and slides will be webcast live and available for up to 90 days via the webcast link above and on Adastra’s website at www.adastrarx.com.